FDA Withdraws 40 New Drug Applications Due to Delays in Annual Reports

Summary

The Food and Drug Administration (FDA) has withdrawn 40 new drug applications (NDA's) submitted by Sperti Drug Products, Inc., et al., after the applicants repeatedly failed to submit required annual reports on these applications, as mandated by law.